Connor, Clark & Lunn Investment Management (CC&L)
CBIO

Connor, Clark & Lunn Investment Management (CC&L)’s Crescent Biopharma CBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,808
Closed -$542K – 1494
2024
Q1 		$542K Buy
1,808
+374
+26% +$112K ﹤0.01% 1083
2023
Q4 		$338K Sell
1,434
-57
-4% -$8.86K ﹤0.01% 1145
2023
Q3 		$224K Sell
1,491
-71
-5% -$11.2K ﹤0.01% 1216
2023
Q2 		$272K Sell
1,562
-28
-2% -$4.7K ﹤0.01% 1127
2023
Q1 		$200K Buy
1,590
+937
+143% +$211K ﹤0.01% 1098
2022
Q4 		$198K Buy
+653
New +$96.3K ﹤0.01% 1056
2022
Q2 		– Sell
-899
Closed -$103K – 1102
2022
Q1 		$103K Sell
899
-295
-25% -$34.6K ﹤0.01% 974
2021
Q4 		$172K Buy
1,194
+71
+6% +$12.9K ﹤0.01% 996
2021
Q3 		$246K Buy
1,123
+59
+6% +$12.5K ﹤0.01% 914
2021
Q2 		$247K Sell
1,064
-215
-17% -$54.7K ﹤0.01% 883
2021
Q1 		$385K Sell
1,279
-4
-0.3% -$1.43K ﹤0.01% 825
2020
Q4 		$482K Buy
1,283
+152
+13% +$53.3K ﹤0.01% 730
2020
Q3 		$347K Buy
1,131
+192
+20% +$73.4K ﹤0.01% 769
2020
Q2 		$353K Sell
939
-368
-28% -$104K ﹤0.01% 819
2020
Q1 		$298K Sell
1,307
-19
-1% -$7.26K ﹤0.01% 800
2019
Q4 		$701K Sell
1,326
-9
-0.7% -$4.87K ﹤0.01% 609
2019
Q3 		$575K Buy
+1,335
New +$859K ﹤0.01% 651
2016
Q4 		– Sell
-138
Closed -$99K – 921
2016
Q3 		$99K Sell
138
-20
-13% -$15.3K ﹤0.01% 776
2016
Q2 		$115K Sell
158
-17
-10% -$11.7K ﹤0.01% 793
2016
Q1 		$104K Sell
175
-13
-7% -$6.67K ﹤0.01% 766
2015
Q4 		$108K Buy
188
+9
+5% +$5.96K ﹤0.01% 752
2015
Q3 		$100K Buy
179
+33
+23% +$23.8K ﹤0.01% 669
2015
Q2 		$116K Buy
146
+11
+8% +$9.1K ﹤0.01% 583
2015
Q1 		$112K Buy
+135
New +$105K ﹤0.01% 529

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CBIO Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 1,808 shares — an estimated $542K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CBIO in Q1 2015 and held it in 24 quarters. The position peaked at $701K in Q4 2019. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,808 Crescent Biopharma shares in Q2 2024, an estimated $542K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Crescent Biopharma in Q1 2015 and held it in 24 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Crescent Biopharma position peaked at $701K in Q4 2019.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.